Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors.

Authors:
Laurent PA; Morel D; Meziani L; Depil S; Deutsch E.

Journal:
Oncoimmunology

Publication Year: 2022

DOI:
10.1080/2162402X.2022.2158013

PMCID:
PMC9788698

PMID:
36567802

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Oncoimmunology

Abbreviation: Oncoimmunology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Allergy and Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor ac…
Albu DI; Wolf BJ; Qin Y and 12 more (2024) - Transparency Score: 2/6
An oncogene regulating chromatin favors response to immunotherapy: Oncogene CHAF1A and immunotherap…
Ying L; Hu Z; Lu Y and 11 more (2024) - Transparency Score: 2/6
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Glöckner HJ; Martinenaite E; Landkildehus Lisle T and 5 more (2024) - Transparency Score: 3/6
Expression of GPX4 by oncolytic vaccinia virus can significantly enhance CD8<sup>+</sup>T cell func…
Wei W; Tian L; Zheng X and 6 more (2024) - Transparency Score: 3/6
Extracellular vesicles released by cancer-associated fibroblast-induced myeloid-derived suppressor …
Ramil CP; Xiang H; Zhang P and 10 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement E.D. reports grants and personal fees from Roche Genentech; grants from Servier; grants from AstraZeneca; grants and personal fees from Merck-Serono; grants from BMS; and grants from MSD outside the submitted work. S.D. is the founder of ErVaccine Technologies. The remaining authors declare that no conflict of interest exists."

Evidence found in paper:

"Disclosure statement: E.D. reports grants and personal fees from Roche Genentech; grants from Servier; grants from AstraZeneca; grants and personal fees from Merck-Serono; grants from BMS; and grants from MSD outside the submitted work. S.D. is the founder of ErVaccine Technologies. The remaining authors declare that no conflict of interest exists."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025